Last updated: February 27, 2026
What is the Drug Associated with NDC 63323-0815?
NDC 63323-0815 corresponds to Vyepti (eptinezumab), a monoclonal antibody indicated for the preventive treatment of migraine in adults. It was approved by the U.S. Food and Drug Administration (FDA) in February 2020. Vyepti is administered intravenously every three months.
Market Landscape
Current Market Size
The migraine prophylactic market has experienced growth driven by increased awareness, reimbursement coverage, and the expansion of biologic therapies. The global migraine drug market was valued at approximately $4.8 billion in 2021 and is projected to reach $7.4 billion by 2028, with a compound annual growth rate (CAGR) of 6.5% [1].
In the U.S., the migraine prophylactic segment accounts for roughly 45% of the total migraine drug sales, comprising both oral preventives and injectable biologics. NDC 63323-0815, as an anti-CGRP monoclonal antibody, targets acute niche consumers and specialty clinics.
Competitor Overview
The main competitors include:
| Drug |
Class |
Dosing |
Approximate Annual Sales (2022) |
Approval Year |
Notes |
| Aimovig (erenumab) |
Anti-CGRP receptor antibody |
Monthly injection |
$700 million |
2018 |
First anti-CGRP monoclonal antibody approved for migraine |
| Ajovy ( fremanezumab) |
Anti-CGRP antibody |
Monthly or quarterly |
$350 million |
2018 |
Flexible dosing schedule |
| Emgality (galcanezumab) |
Anti-CGRP antibody |
Monthly or quarterly |
$300 million |
2018 |
Also indicated for cluster headaches |
| Vyepti (eptinezumab) |
Anti-CGRP antibody |
Quarterly IV infusion |
$150 million |
2020 |
Approved for preventive migraine management |
Market Penetration and Adoption
Vyepti's intravenous delivery offers an alternative for patients with gastrointestinal issues or those preferring less frequent dosing. Its small market share (estimated at 10-15% of the anti-CGRP class) is expected to increase with expanded physician awareness and ongoing clinical trials.
Access and Reimbursement
Coverage for anti-CGRP therapies is generally favorable in the U.S., with most insurers covering Vyepti following prior authorization. Pricing strategies and rebates influence pharmacy costs and payor reimbursements.
Price Projection Models
Current Pricing
Vyepti's list price (as of early 2023) is approximately $5,000 per infusion. The quarterly schedule results in an annual cost of roughly $20,000 per patient.
Competitive Pricing Range
| Drug |
Approximate List Price per Dose |
Annual Cost |
Route of Administration |
Dosing Frequency |
| Aimovig |
$575 (monthly injection) |
~$6,900 |
Subcutaneous |
Monthly |
| Ajovy |
$575 (monthly injection) |
~$6,900 |
Subcutaneous |
Monthly |
| Emgality |
$600 (monthly infusion) |
~$7,200 |
Subcutaneous |
Monthly |
| Vyepti |
$5,000 |
$20,000 |
Intravenous |
Quarterly |
Short-Term Price Trends (2023-2027)
- Price stabilization expected due to payer negotiations and biosimilar encroachments.
- Potential discounts of 10-15% annually through rebates and value-based contracts.
- Market share increase anticipated as physicians opt for IV formulations and integrated care models.
Long-Term Price Outlook (2028 and beyond)
- Pricing reduction of up to 20% likely as biosimilar monoclonal antibodies enter the market, targeting the anti-CGRP segment.
- Rebate-driven pricing could drive net prices down by 25-30%.
- Emergence of generic or biosimilar options may force prices below $4,500 per infusion.
Regulatory and Policy Impact
- The FDA maintains a favorable stance toward biologics, with streamlined pathways for biosimilar approval.
- Price caps or negotiations at the federal level could influence list prices.
- Reimbursement policies, especially under Medicare and Medicaid, may lead to price adjustments.
Key Takeaways
- NDC 63323-0815, Vyepti, holds a niche position with potential to grow in the migraine preventive market.
- Current list price: approximately $5,000 per infusion; annual cost: $20,000.
- Competition mainly consists of subcutaneous anti-CGRP antibodies, with similar pricing levels.
- Market share growth depends on physician preference, patient acceptance, and payer reimbursement strategies.
- Long-term pricing is likely to decline due to biosimilar competition and negotiated discounts.
FAQs
Q1: What is the primary advantage of Vyepti over other anti-CGRP therapies?
A1: Vyepti is administered intravenously quarterly, which can reduce treatment frequency and improve adherence for specific patient populations.
Q2: How does Vyepti's pricing compare to its oral competitors?
A2: Oral CGRP antagonists like ubrogepant or rimegepant have lower annual costs (typically under $2,000), but they are designed for acute treatment, not prevention.
Q3: Are biosimilar versions of Vyepti expected?
A3: Biosimilar development is unlikely within the next 3-5 years due to the complexity of monoclonal antibody manufacturing, but policy changes could alter this timeline.
Q4: How is reimbursement structured for intravenously administered migraine preventives?
A4: Reimbursement varies but generally includes reimbursement for drug costs, administration fees, and related facility charges, with coverage heavily influenced by payer policies.
Q5: What is the outlook for patient adoption of Vyepti?
A5: Adoption may increase as awareness grows, especially among those who require less frequent dosing or have contraindications to subcutaneous options.
References
- MarketsandMarkets. (2022). Migraine Drugs Market by Type, Drug Class, Route of Administration, and Region. Retrieved from https://www.marketsandmarkets.com
